<DOC>
	<DOC>NCT00456716</DOC>
	<brief_summary>Open label study of sorafenib</brief_summary>
	<brief_title>Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma</brief_title>
	<detailed_description>Open label study using oral sorafenib 800 mg daily in any stage III-IV BAC lung cancer and Stage III-IV adenocarcinoma of the lung in nonsmokers (less than &lt; 100 cigarettes lifetime).</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Age &gt; 18 Life expectancy &gt; 12 weeks Biopsyproven BAC or adenocarcinoma Willing to provide smoking status Selected IIIB or stage IV cancer that is incompletely resected or unresectable O2 saturation &lt; 88% on room air Pregnant or nursing women Surgery or radiation therapy within 4 weeks of starting study Major heart condition within 6 months of starting therapy Certain concomitant medications prohibited</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>BAC lung cancer</keyword>
	<keyword>adenocarcinoma of the lung</keyword>
</DOC>